Effect of a multifaceted intervention to improve clinical quality of care through stepwise certification (SafeCare) in health-care facilities in Tanzania: a cluster-randomised controlled trial.
Certification
Faith-Based Organizations
Guideline Adherence
/ statistics & numerical data
Health Facilities
/ standards
Humans
Infection Control
/ standards
Practice Guidelines as Topic
Private Sector
Program Evaluation
Quality Improvement
/ organization & administration
Quality of Health Care
/ statistics & numerical data
Tanzania
Journal
The Lancet. Global health
ISSN: 2214-109X
Titre abrégé: Lancet Glob Health
Pays: England
ID NLM: 101613665
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
27
10
2020
revised:
29
04
2021
accepted:
05
05
2021
pubmed:
8
8
2021
medline:
26
8
2021
entrez:
7
8
2021
Statut:
ppublish
Résumé
Quality of care is consistently shown to be inadequate in health-care settings in many low-income and middle-income countries, including in private facilities, which are rapidly growing in number but often do not have effective quality stewardship mechanisms. The SafeCare programme aims to address this gap in quality of care, using a standards-based approach adapted to low-resource settings, involving assessments, mentoring, training, and access to loans, to improve clinical quality and facility business performance. We assessed the effect of the SafeCare programme on quality of patient care in faith-based and private for-profit facilities in Tanzania. In this cluster-randomised controlled trial, health facilities were eligible if they were dispensaries, health centres, or hospitals in the faith-based or private for-profit sectors in Tanzania. We randomly assigned facilities (1:1) using computer-generated stratified randomisation to receive the full SafeCare package (intervention) or an assessment only (control). Implementing staff and participants were masked to outcome measurement and the primary outcomes were measured by fieldworkers who had no knowledge of the study group allocation. The primary outcomes were health worker compliance with infection prevention and control (IPC) practices as measured by observation of provider-patient interactions, and correct case management of undercover standardised patients at endline (after a minimum of 18 months). Analyses were by modified intention to treat. The trial is registered with ISRCTN, ISRCTN93644888. Between March 7 and Nov 30, 2016, we enrolled and randomly assigned 237 health facilities to the intervention (n=118) or control (n=119). Nine facilities (seven intervention facilities and two control facilities) closed during the trial and were not included in the analysis. We observed 29 608 IPC indications in 5425 provider-patient interactions between Feb 7 and April 5, 2018. Health facilities received visits from 909 standardised patients between May 3 and June 12, 2018. Intervention facilities had a 4·4 percentage point (95% CI 0·9-7·7; p=0.015) higher mean SafeCare standards assessment score at endline than control facilities. However, there was no evidence of a difference in clinical quality between intervention and control groups at endline. Compliance with IPC practices was observed in 8181 (56·9%) of 14 366 indications in intervention facilities and 8336 (54·7%) of 15 242 indications in control facilities (absolute difference 2·2 percentage points, 95% CI -0·2 to -4·7; p=0·071). Correct management occurred in 120 (27·0%) of 444 standardised patients in the intervention group and in 136 (29·2%) of 465 in the control group (absolute difference -2·8 percentage points, 95% CI -8·6 to -3·1; p=0·36). SafeCare did not improve clinical quality as assessed by compliance with IPC practices and correct case management. The absence of effect on clinical quality could reflect a combination of insufficient intervention intensity, insufficient links between structural quality and care processes, scarcity of resources for quality improvement, and inadequate financial and regulatory incentives for improvement. UK Health Systems Research Initiative (Medical Research Council, Economic and Social Research Council, UK Department for International Development, Global Challenges Research Fund, and Wellcome Trust).
Sections du résumé
BACKGROUND
Quality of care is consistently shown to be inadequate in health-care settings in many low-income and middle-income countries, including in private facilities, which are rapidly growing in number but often do not have effective quality stewardship mechanisms. The SafeCare programme aims to address this gap in quality of care, using a standards-based approach adapted to low-resource settings, involving assessments, mentoring, training, and access to loans, to improve clinical quality and facility business performance. We assessed the effect of the SafeCare programme on quality of patient care in faith-based and private for-profit facilities in Tanzania.
METHODS
In this cluster-randomised controlled trial, health facilities were eligible if they were dispensaries, health centres, or hospitals in the faith-based or private for-profit sectors in Tanzania. We randomly assigned facilities (1:1) using computer-generated stratified randomisation to receive the full SafeCare package (intervention) or an assessment only (control). Implementing staff and participants were masked to outcome measurement and the primary outcomes were measured by fieldworkers who had no knowledge of the study group allocation. The primary outcomes were health worker compliance with infection prevention and control (IPC) practices as measured by observation of provider-patient interactions, and correct case management of undercover standardised patients at endline (after a minimum of 18 months). Analyses were by modified intention to treat. The trial is registered with ISRCTN, ISRCTN93644888.
FINDINGS
Between March 7 and Nov 30, 2016, we enrolled and randomly assigned 237 health facilities to the intervention (n=118) or control (n=119). Nine facilities (seven intervention facilities and two control facilities) closed during the trial and were not included in the analysis. We observed 29 608 IPC indications in 5425 provider-patient interactions between Feb 7 and April 5, 2018. Health facilities received visits from 909 standardised patients between May 3 and June 12, 2018. Intervention facilities had a 4·4 percentage point (95% CI 0·9-7·7; p=0.015) higher mean SafeCare standards assessment score at endline than control facilities. However, there was no evidence of a difference in clinical quality between intervention and control groups at endline. Compliance with IPC practices was observed in 8181 (56·9%) of 14 366 indications in intervention facilities and 8336 (54·7%) of 15 242 indications in control facilities (absolute difference 2·2 percentage points, 95% CI -0·2 to -4·7; p=0·071). Correct management occurred in 120 (27·0%) of 444 standardised patients in the intervention group and in 136 (29·2%) of 465 in the control group (absolute difference -2·8 percentage points, 95% CI -8·6 to -3·1; p=0·36).
INTERPRETATION
SafeCare did not improve clinical quality as assessed by compliance with IPC practices and correct case management. The absence of effect on clinical quality could reflect a combination of insufficient intervention intensity, insufficient links between structural quality and care processes, scarcity of resources for quality improvement, and inadequate financial and regulatory incentives for improvement.
FUNDING
UK Health Systems Research Initiative (Medical Research Council, Economic and Social Research Council, UK Department for International Development, Global Challenges Research Fund, and Wellcome Trust).
Identifiants
pubmed: 34363766
pii: S2214-109X(21)00228-X
doi: 10.1016/S2214-109X(21)00228-X
pmc: PMC8370880
pii:
doi:
Banques de données
ISRCTN
['ISRCTN93644888']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1262-e1272Subventions
Organisme : Medical Research Council
ID : MR/N015061/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N015061/1
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests This study, through the Health Systems Research Initiative, was partly funded by the UK Government's Department for International Development, which also funded the SafeCare intervention through its Human Development Innovation Fund programme.
Références
Bull World Health Organ. 2017 Jul 1;95(7):503-516
pubmed: 28670015
Bull World Health Organ. 2017 May 1;95(5):343-352E
pubmed: 28479635
BMJ. 2008 Sep 29;337:a1655
pubmed: 18824488
Lancet. 2016 Aug 6;388(10044):596-605
pubmed: 27358253
Global Health. 2014 Oct 17;10:68
pubmed: 25927498
Lancet. 2016 Jan 9;387(10014):188-98
pubmed: 26603919
Health Aff (Millwood). 2016 Jul 1;35(7):1214-21
pubmed: 27385236
Cochrane Database Syst Rev. 2016 Dec 02;12:CD008992
pubmed: 27911487
Lancet Glob Health. 2018 Nov;6(11):e1163-e1175
pubmed: 30309799
Health Policy Plan. 2016 Oct;31(8):1117-32
pubmed: 27198979
PLoS Med. 2017 Dec 12;14(12):e1002464
pubmed: 29232377
PLoS Med. 2011 Apr;8(4):e1000433
pubmed: 21532746
J Clin Tuberc Other Mycobact Dis. 2019 Jun 07;16:100109
pubmed: 31720433
J Clin Epidemiol. 2014 Mar;67(3):267-77
pubmed: 24275499
Bull World Health Organ. 2020 Dec 1;98(12):849-858A
pubmed: 33293745
Lancet Glob Health. 2018 Feb;6(2):e211-e221
pubmed: 29275135
PLoS One. 2012;7(11):e48457
pubmed: 23152775
BMJ Glob Health. 2017 Jun 10;2(2):e000333
pubmed: 29225937
Jt Comm J Qual Patient Saf. 2016 Aug;42(8):350-71
pubmed: 27456416
Lancet. 2016 Aug 6;388(10044):613-21
pubmed: 27358250
Lancet Glob Health. 2018 Nov;6(11):e1196-e1252
pubmed: 30196093
PLoS One. 2019 Dec 20;14(12):e0226804
pubmed: 31860657
J Econ Perspect. 2008 Spring;22(2):93-114
pubmed: 19768841
Lancet Glob Health. 2020 Jun;8(6):e780-e789
pubmed: 32389195
J Hypertens. 2020 Feb;38(2):362-367
pubmed: 31584515
Lancet. 2016 Aug 6;388(10044):606-12
pubmed: 27358251